(NASDAQ: INMB) Inmune Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.56%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.96%.
Inmune Bio's earnings in 2026 is -$49,887,000.On average, 6 Wall Street analysts forecast INMB's earnings for 2026 to be -$25,128,386, with the lowest INMB earnings forecast at -$28,919,444, and the highest INMB earnings forecast at -$20,098,455. On average, 5 Wall Street analysts forecast INMB's earnings for 2027 to be -$26,393,844, with the lowest INMB earnings forecast at -$35,432,832, and the highest INMB earnings forecast at -$14,236,406.
In 2028, INMB is forecast to generate -$21,151,231 in earnings, with the lowest earnings forecast at -$32,566,941 and the highest earnings forecast at -$8,653,501.